AI Article Synopsis
- The study investigates apoptosis and proliferation markers (Bcl2, p53, Ki-67, CyclD1) and the neuroendocrine marker Chromogranin A in relation to the radioresistance of rectal cancer.
- Statistically significant differences were noted in p53, Ki-67, and Chromogranin A expression among patients with different prognoses post-radiotherapy.
- Higher levels of Chromogranin A were strongly associated with poorer prognosis, suggesting that neuroendocrine activity may increase tumor aggressiveness.
Article Abstract
The aim of this study is to reveal the potential roles of apoptosis markers (Bcl2 and p53), proliferation markers (Ki-67 and CyclD1), and the neuroendocrine marker Chromogranin A as markers for the radioresistance of rectal cancer. Statistically significant differences were found in the expression of p53, Ki-67, and Chromogranin A in groups of patients with and without a favorable prognosis after radiotherapy. The survival analysis revealed that the marker of neuroendocrine differentiation, Chromogranin A, also demonstrated a high prognostic significance, indicating a poor prognosis. Markers of proliferation and apoptosis had no prognostic value for patients who received preoperative radiotherapy. Higher Chromogranin A values were predictors of poor prognosis. The results obtained from studying the Chromogranin A expression suggest that the secretion of biologically active substances by neuroendocrine cells causes an increase in tumor aggressiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839263 | PMC |
| http://dx.doi.org/10.3390/molecules27030596 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!